"With the first ten CoreTherm® Eagle machines manufactured, we see great opportunities to provide more clinics, both in the Nordic region and internationally, with the possibility to offer an effective, outpatient treatment for benign prostate enlargement. Together we can improve the quality of life for men with prostate problems."
Third quarter
July 1 - September 30
- Net sales reached SEK 3,5 million (4,8)
- Operating profit/loss totaled SEK -4,4 million (-6,2)
- Loss after taxes SEK -4,5 million (-6,3)
- Earnings per share, SEK before and after dilution amounted to SEK -0,04 (-0,08)
- Cash flow from operating activities amounted to SEK -3,4 million (-11,9)
January 1 - September 30
- Net sales reached SEK 9,8 million (10,9)
- Operating profit/loss totaled SEK -16,3 million (-13,4)
- Loss after taxes SEK -16,5 million (-13,5)
- Earnings per share, SEK before and after dilution amounted SEK -0,18 (-0,21)
- Cash flow from operating activities amounted to SEK -16,1 million (-17,9)
- Cash and cash equivalents amounted to SEK 12,1 million (22,5)
Significant events during the period
- On July 3, ProstaLund announced that it is carrying out a directed issue of units to the guarantor in connection with the completed rights issue.
- ProstaLund informed on July 11 to return with an announcement last day of trading in BTU after the rights issue has been registered.
- ProstaLund announced on July 17 the last day of trading in BTUs and first day of trading in warrants of series TO 3.
- First patients treated with CoreTherm® Concept in Austria.
- Published study confirms the good effect of transurethral intraprostatic anesthesia (TUIA) via Schelin Catheter®.
- Prostalund's CEO and CFO have acquired shares and warrants.
Significant events after the end of the period
- First published report of transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® in patients undergoing holmium laser enucleation of the prostate.
- Short-term results and long-term durability after CoreTherm® treatments pre- sented at the Emirates International Urological Conference in Dubai, UAE.
- Notice of Extraordinary General Meeting regarding decision on reverse share split.
Key figures
| (SEK MILLION) | JUL-SEP 2024 | JUL-SEP 2023 | JAN-SEP 2024 | JAN-SEP 2023 |
| Net sales | 3,5 | 4,8 | 9,8 | 15,6 |
| Gross Margin (%) | 62,9 | 73,2 | 68,6 | 69,5 |
| Operating profit/loss, EBIT | -4,4 | -6,2 | -16,3 | -13,4 |
| Cash flow from operating activites | -3,4 | -11,9 | -16,1 | -17,9 |
| Cash and cash equivalents | 12,1 | 22,5 | 12,1 | 22,5 |
| Average number of employees | 9 | 9 | 7 | 9 |
For further information, please contact:
Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com
About ProstaLund
ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPE). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 3,600 shareholders. For more information, visit www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden
Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se
This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-07 07:30 CET.
